SymBio Pharmaceuticals
SymBio Pharmaceuticals aims to develop drugs for patients overlooked by the industry, ensuring vital treatments reach those in need.
Market cap
$64.4m
Enterprise value
$42m
Share price
JPY170.00 4582.T
loading funding rounds…
Cephalon(exited)
DBJ Capital(exited)
Daiichi Sankyo(exited)
TNP(exited)
VALUE CREATION(exited)
Japan Asia Investment(exited)
Mizuho Capital(exited)
Mitsubishi UFJ Capital(exited)
Waseda University(exited)
SBI Investment(exited)
Nippon Venture Capital(exited)
Nissay Capital(exited)
| JPY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 5 % | 176 % | 21 % | (44 %) | (56 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (150 %) | (166 %) | 13 % | 20 % | (4 %) | (153 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (154 %) | (137 %) | 25 % | 12 % | (35 %) | (156 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.